The Pharmaceutical Research and Manufacturers of America has joined two other associations in a federal lawsuit challenging the price-setting provisions of the Inflation Reduction Act.

PhRMA, along with the Global Colon Cancer Association and the National Infusion Center Association, assert that the IRA is unconstitutional, including what the groups call an excise tax threat for noncompliance to agree to prices set by the federal government. The tax can reach as high as 1,900% of a manufacturer's total U.S. revenues for a drug, they said. "It is no negotiation at all," the lawsuit said. "It is a government mandate disguised as negotiation. And it is unconstitutional, on several grounds."

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.